Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.

Slides:



Advertisements
Similar presentations
Giancarlo Agnelli Università di Perugia Anticoagulant treatment for PE: optimal duration.
Advertisements

Acute venous or arterial thrombosis Acute venous or arterial thrombosis Is there an indication for thrombolysis? Baseline labs: CBC, PT, PTT, fibrinogen.
Rocky Mountain ACP Internal Medicine Conference November 22, 2012 Brian Wirzba, MD, FRCPC, FACP.
Brian M. Johnson, MD CCRMC PBL 11/7/12
Suresh Vedantham, M.D. Interventional Radiologist Associate Professor of Radiology & Surgery Washington University School of Medicine Vice-Chair, Venous.
Aggressive Management of Chronic Deep Venous Thrombosis: Technical and Clinical Outcomes Mark J. Garcia M.D. FSIR C Grilli, M McGarry, M Ali, D Agriantonus,
Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc Tel: Richmond 9/29/2006 Venous.
Results: 1.Progression of thrombus length and volume (40% vs. 28%; P
Post thrombotic Syndrome Godwin Tse LA-TRAP Winter 2011.
Long-Term Outcome After Additional Catheter-Directed Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis (The CaVenT Study):
Chapter Eleven Venous Disease Coalition Chronic Venous Insufficiency VTE Toolkit.
Joint Hospital Surgical Grand Round
Venous thromboembolism –
RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.
Deep vein thrombosis David Hughes. Pathophysiology normal deep pelvic/leg veins thrombus (red cells, fibrin) around valves propagation Virchow’s triad.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Management of DVT Soheir Adam, MD, MSC, FRCPath
Venous thromboembolism: how long to treat?
Chapter Two Venous Disease Coalition Pathogenesis and Consequences of VTE VTE Toolkit.
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
Chapter Nine Venous Disease Coalition New Therapies for VTE VTE Toolkit.
Chapter Three Venous Disease Coalition Epidemiology of VTE Risks, Risk Factors VTE Toolkit.
The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Epidemiology and diagnosis of acute pulmonary embolism Dr Sam Z Goldhaber Associate Professor of Medicine Harvard Medical School Staff Cardiologist Brigham.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Pulmonary Embolism and Infarction
Cancer-Associated Thrombosis
7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
Spotlight Case May 2003 Central Line Complications in an Infant webmm.ahrq.gov.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Hypercoagulable Syndromes. Risk Factors For Venous Thrombosis ACQUIREDINHERITEDMIXED/UNKNOWN Advancing ageAntithrombin Deficiency  Homocysteine ObesityProtein.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
MANAGEMENT OF POST-ENDOVENOUS ABLATION VENOUS THROMBOSIS Stephen F. Daugherty, MD, FACS Clarksville, Tennessee, USA.
HICKMAN CATHETER Thrombotic complications associated with venous access devic Thrombotic complications associated with venous access devices Occlusion.
Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
CHRONIC ILIOFEMORAL DVT NEVER TOO LATE Stephen F. Daugherty, MD, FACS, RVT, RPhS Clarksville, Tennessee ACP NOVEMBER, 2012.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,
Risk Assessment for VTE. Which of the following best describes you?
Ambulatory Venous Hypertension Components Obstruction Valve incompetence Obstruction Valve incompetence Obstruction and valve incompetence …Highest venous.
Case 2: IVC Filters 44 y/o male “preaching pastor” 10/23Generalized seizure Large AVM 2/12Embolization, left frontal craniotomy and resection c/b right.
Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing June 2012 NICE clinical guideline.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
N ENGL J MED 호흡기내과 R1 윤수진 SCREENING FOR OCCULT CANCER IN UNPROVOKED VENOUS THROMBOEMBOLISM.
Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.
Venous Thromboembolic Disease: The Role of Novel Anticoagulants Grant M. Greenberg MD, MA, MHSA.
Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-LegColor-CodedDopplerUltrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis A Randomized.
Outpatient DVT assessment & treatment Daniel Gilada.
Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας Διαχείριση αντιπηκτικής αγωγής εν όψει προγραμματισμένων επεμβατικών πράξεων.
Epidemiology and Natural history of Venous Obstruction/Compression
Current Standards for Treatment of DVT
Deep Venous Thrombosis Anthony J. Comerota, MD, FACS, FACC
The relation between venous and arterial thrombosis
Extended Treatment of VTE: Who is the Right Candidate?
Rome, 15th December 2015 Valeria Maida Medical Affairs
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
HICKMAN CATHETER. HICKMAN CATHETER Thrombotic complications associated with venous access devices Occlusion of lumen Fibrin sheath formation Venous.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Extending Treatment for Thrombosis: What’s the Right Choice?
Post-thrombotic Syndrome.
Disease Burden of VTE Phases of VTE Treatment.
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Presentation transcript:

Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk Concurrent cancer Thrombophilia or prognostic marker Idiopathic Deep Vein Thrombosis

Patient Category Duration 3 months 6-12 months Consider indefinite 6-12 months Consider indefinite 12 months (consider indefinite) LMWH x 3-6 months Anticoag. Indefinitely or cancer cured LMWH x 3-6 months Anticoag. Indefinitely or cancer cured Transient Idiopathic Cancer Thrombophilia Recurrent DVT Indefinite ACCP CHEST 2004 Deep Vein Thrombosis Duration of Anticoagulation

Acute DVT Stopping Anticoagulation Considerations 1.Does patient have persistent venous thrombosis? 2.Is there persistent thrombus activity? ….impact on duration of anticoagulation 1.Does patient have persistent venous thrombosis? 2.Is there persistent thrombus activity? ….impact on duration of anticoagulation

Recurrent VTE Residual Venous Thrombus Time after Initial DVT, mo Cumulative Proportion of Patients with Recurrent VTE Prandoni, P et al Ann Intern Med 2002;137:955 Prandoni, P et al Ann Intern Med 2002;137:955

Recurrent VTE: Prospective Study Patient Characteristics Thrombophilia Idiopathic Secondary 2 years Characteristic 15% 7% 4% All 10.3% 4.4% 0% US Normal 23% 7.5% 7.1% US Abnormal Prandoni, P et al Ann Intern Med 2002;137:955 Prandoni, P et al Ann Intern Med 2002;137:955

Recurrent VTE D-Dimer Eichinger S et al JAMA 2003; 290: 1071 Eichinger S et al JAMA 2003; 290: 1071 Probability of Recurrence at 3 Years < 250 ng/ml 3.7%* > 250 ng/ml 11.5% P = % lower risk of recurrence*

Associated with Severe Postthrombotic Morbidity! O'Donnell TMavor GEBeyth RJ J Surg Res. 1977Br J Surg 1969Arch Int Med 1995 O'Donnell TMavor GEBeyth RJ J Surg Res. 1977Br J Surg 1969Arch Int Med 1995 Iliofemoral DVT Natural History

Anticoagulation Long-Term Venous Function 20 patients with iliofemoral DVT Conventional anticoagulation Followed 5 years Long-Term Venous Function 20 patients with iliofemoral DVT Conventional anticoagulation Followed 5 years Akesson H, Eur J Vasc Surg 1990 Iliofemoral DVT

5 yrs Calf Muscle Dysfunction Ambulatory Venous Hypertension Venous Insufficiency Venous Claudication Venous Ulceration 5 yrs Calf Muscle Dysfunction Ambulatory Venous Hypertension Venous Insufficiency Venous Claudication Venous Ulceration % 50% 95% 90% 15% % 50% 95% 90% 15% Iliofemoral DVT Akesson H, Eur J Vasc Surg 1990 Anticoagulation

Iliofemoral DVT Rationale for Thrombus Removal A strategy of thrombus removal reduces the risk of postthrombotic syndrome!